Fresenius Medical Care AG & Co. KGaA $FMS Position Boosted by Sei Investments Co.

Sei Investments Co. grew its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 80.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,704 shares of the company’s stock after purchasing an additional 53,922 shares during the period. Sei Investments Co.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $2,723,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Morgan Stanley grew its position in Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Pzena Investment Management LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 2.0% in the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock worth $339,592,000 after buying an additional 299,986 shares in the last quarter. Bank of America Corp DE lifted its position in Fresenius Medical Care AG & Co. KGaA by 279.7% in the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after buying an additional 248,477 shares in the last quarter. ABC Arbitrage SA boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% during the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after buying an additional 229,589 shares during the period. Finally, Integral Health Asset Management LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after buying an additional 200,000 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.7%

NYSE:FMS opened at $24.27 on Friday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The firm has a market cap of $13.04 billion, a price-to-earnings ratio of 12.58, a P/E/G ratio of 4.29 and a beta of 0.77. The company has a quick ratio of 0.86, a current ratio of 1.07 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $23.59 and its 200-day moving average is $23.02.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The business had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.22 EPS for the current year.

Wall Street Analyst Weigh In

FMS has been the topic of a number of research reports. BNP Paribas Exane downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a research note on Tuesday, July 28th. Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research report on Friday, May 8th. Weiss Ratings restated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, May 6th. Finally, Truist Financial set a $25.00 price target on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday. Six investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Reduce” and an average price target of $23.57.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.